医药行业周报：GRIN在研疗法Radiprodil获FDA突破性疗法认定

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [6]. Core Insights - GRIN's investigational therapy Radiprodil has received breakthrough therapy designation from the FDA for treating epilepsy in patients with GRIN-related neurodevelopmental disorders. The company plans to initiate a pivotal Phase 3 clinical trial in mid-2025 [2][6]. - The pharmaceutical sector showed a market performance increase of 1.18% on February 26, 2025, outperforming the CSI 300 index by 0.31 percentage points, ranking 9th among 31 sub-industries [1][6]. - Notable performers in the pharmaceutical sector included medical research outsourcing (+2.62%) and other biological products (+2.28%), while medical devices (-0.10%) and vaccines (+0.03%) lagged behind [1]. Company Summaries - Nanwei Technology (688690) reported a revenue of 783 million yuan for 2024, a year-on-year increase of 33.36%, with a net profit of 81 million yuan, up 18.29% [2]. - Aotai Biotech (688606) achieved a revenue of 870 million yuan in 2024, reflecting a 15.25% growth, and a net profit of 304 million yuan, up 68.18% [2]. - Xuantai Pharmaceutical (688247) reported a revenue of 513 million yuan for 2024, a significant increase of 70.97%, with a net profit of 128 million yuan, up 109.97% [3]. - Innotech (688253) achieved a revenue of 621 million yuan in 2024, a 29.98% increase, with a net profit of 246 million yuan, up 41.24% [3]. - Gongtong Pharmaceutical (300966) announced a stock repurchase plan with a total amount of 20-30 million yuan, aiming to buy back approximately 839,102 to 1,258,653 shares [3].